CAR T-Cell Therapy Services for Multiple Myeloma Prior Authorization
Defines prior authorization documentation and clinical criteria for coverage of BCMA-directed CAR T-cell therapy for members with relapsed or refractory multiple myeloma, including required prior lines of therapy, disease relapse/refractory definitions, organ/infection status, and billing code guidance.
No material clinical/coverage changes
Coverage Summary
This policy covers with criteria prior authorization for BCMA‑directed CAR T‑cell therapies for members with relapsed or refractory multiple myeloma. It defines required documentation and clinical criteria that must be met before infusion, including prior lines of therapy, organ and infection status, age, and that the patient has not previously received an FDA‑approved BCMA‑directed CAR T therapy.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.